Louis Bowen, MBA, is the Executive Chairman and Director of Finance of Pacific GeneTech Limited which he co-founded in 2009. He also currently serves as the Chairman and CEO of Asia Capital Management Limited, a private investment banking company based in Hong Kong that he founded in 1994.
Previously, he served as Managing Director of Arral and Partners Limited, one of the first private investment companies in Asia. Louis started his career with Citigroup in New York, before relocating to Hong Kong to establish the Citigroup corporate finance activities in Asia. Louis has overseen many investments and acquisitions in Asia across a range of industries including pharmaceuticals, primary care services, and medical diagnostics.
Louis has served on the boards of a number of companies during his professional career and currently serves on the Advisory Council of the Hong Kong University of Science and Technology Business School, The Dean’s Executive Advisory Board of the Walton School of Business at the University of Arkansas, the Board of Governors of the Wharton Alumni Association of Hong Kong and the Board of Advisors of the Arkansas World Trade Center.
He was a co-founder of the Hong Kong Venture Capital Association. He is a member of the Hong Kong Forum, an Asian regional think-tank affiliated with the US Council on Foreign Relations, and has been a member of the Hong Kong Chapter of the YPO/WPO organization.
Louis holds an MBA in Finance from the Wharton School and has a BA in Economics from the University of Arkansas.
James Brown, CPA, JD, is Managing Director of AVG Ventures, an investment firm specialising in early to mid-stage technology companies. Prior to joining AVG Ventures, Mr Brown was an independent investor and Member of the Board for numerous companies. Before that, he served in several executive operating roles in public and private technology companies, with responsibilities ranging from finance and legal to operations and strategy.
Previously, Mr Brown was Executive Vice President and General Manager of OpenTV, Inc., a technology and media company which he helped to take public.He was also responsible for founding and managing the company’s applications business unit until its sale to Liberty Media.
Mr Brown started his career practicing law, specialising in corporate finance and technology transactions. He served as a Partner at McDermott, Will & Emery in Menlo Park and Pillsbury Madison & Sutro in San Francisco.
Mr Brown holds a Bachelors of Science in Accounting from Weber State University and a Juris Doctorate from Brigham Young University Law School where he was Executive Editor of the Law Review and graduated magna cum laude. He is a Certified Public Accountant (inactive) and an active member of the California Bar Association.
Tim Collard is the Chief Executive Officer of Pacific GeneTech and is responsible for the overall management and operations of the company. Tim has more than 40 years’ experience in the global pharmaceutical and biotechnology industries. In 1975 he started his career working with Connaught Laboratories supplying human vaccines to the Hong Kong government and was also involved in development of Connaught’s veterinary vaccines. In 1977 he was recruited by Califas, a China-based consultancy, where he negotiated the first Sino-US joint manufacturing contract in the Chinese healthcare industry and preliminary joint venture agreements between Squibb and the Chinese government.
In 1980 Tim joined Solvay as Far East Director for Solvay’s Biochem Products division, a joint venture with the Pasteur Institute, which developed human and agricultural biologicals. In 1987 he became General Manager, Far East, of British biopharmaceuticals company Porton International where he established marketing, distribution, and local R&D in Asia for human vaccines and biopharmaceuticals, including Porton’s botulinum toxin for treatment of neurological diseases.
In 1993, Tim served as Vice President of Lotus Healthcare Corporation, a manufacturer of oral controlled-release morphine and dihydrocodeine in China. He was responsible for business development, sourcing of Chinese pharmaceutical raw materials, and all in-licensing and technology transfer. In 1997, he established Phoenix Lifesciences to provide transactional consultancy services to the biotechnology sector in Greater China and Southeast Asia. In this consulting capacity, Tim negotiated a “first mover” supply agreements for bulk antibiotics between a Chinese producer and British pharmaceutical companies. Tim continued to work on a variety of projects with local and multinational companies including AstraZeneca, Authentix, Aventis, bioMérieux, Proctor & Gamble, SciClone, and Xenova.
Tim holds a BS in biology from Bristol University in the United Kingdom.
Frank Kuo, MBA, is responsible for investment activities and investment banking business for Yuanta Financial Holding Group. He holds various positions within the Group, including Chief Corporate Banking Officer of Yuanta Financial Holding Co., Ltd, Executive Vice President of Yuanta Securities Co., Ltd, Board Director of Yuanta Asia Investment Limited, Director of Yuanta Commercial Bank Co., Ltd, Director of Yuanta Securities (Hong Kong) Limited and Consultant of Yuanta Venture Capital Co., Ltd.
Previously, Mr Kuo served as President of Yuanta Venture Capital and Managing Director of Grand Asset Management, Manager of Yuanta Securities, and a Special Assistant to the group’s president and an Assistant Manager of President Securities.
Mr Kuo holds a MBA from the University of Texas in Arlington and a Bachelors in International Business Management from Soochow University, Taiwan.
Stephen Parr, MBA, is President and Managing Member of Parr Financial Group, LLC, an asset management firm broadly focused on China, Asia, and the international markets. Mr Parr has been an active investor in China for over thirty years.
Prior to founding Parr Financial Group, Mr Parr was one of the Managing Directors for Pope Asset Management in the United States. In this role, he was responsible for managing a portfolio ofUS$400million and advised Pope on investment strategy, serving as the macroeconomic and political analyst.
Before joining Pope, Mr Parr successfully consulted on financial and strategic advice to a large number of private and public companies.
Mr Parr also served as a Vice President and International Specialist at Goldman Sachs, where he started his career.
Mr Parr holds a Bachelors Degree from Vanderbilt University and a MBA in Finance from Emory University.
Betty Allen Tucker, JD, is the Director of Development at the University of Arkansas for Medical Sciences Psychiatric Research Institute and President and Director of Rivers Edge Ventures, where she holds 50% ownership of the firm.Previously, she served as the Director of Development for the University of Arkansas for Medical Sciences Myeloma Institute for Research and Therapy. She is an original and current stockholder of Pacific GeneTech and has advised company activities and board meetings since its founding.
From 1982 through 2004 she was President and CEO of Cablevision Management Inc., a cable television company she established with her husband that founded, built, and invested in cable television and fibre optic systems in the United States, Great Britain and Indonesia. The British and Indonesian systems each merged with and became a part of public companies.
In 1996, she was named one of Arkansas’ top 100 business women. After serving as First Lady of Arkansas from 1992-1996, she moved with her husband to Hong Kong for several years, to focus on their cable television investment in Indonesia. During that time, she helped to establish the Hong Kong branch of Heifer International and travelled extensively throughout Asia. Betty has held positions on the governing boards of the Arkansas Arts Center, the Arkansas Children’s Hospital, Second Presbyterian Church, and the Arkansas chapter of the International Women’s Forum.
Mrs Tucker holds a Bachelors and Juris Doctorate from the University of Arkansas at Little Rock.